01 Tianneng Holding Group Chairman Zhang Tianren Visits Far East Horizon, Both Parties Sign Strategic Cooperation Agreement

On October 10, Zhang Tianren, Party Committee Secretary and Chairman of Tianneng Holding Group, a leading global enterprise in the new energy power and energy storage sectors, led a delegation to visit Far East Horizon. He held talks with Kong Fanxing, Chairman of the Board of Directors, Executive Director, and Chief Executive Officer of Far East Horizon, focusing on industrial collaboration, green development, and global layout. The two parties officially signed a strategic cooperation agreement. This cooperation is not only an important practice of Far East Horizon implementing its "Three Transformations and Two Services" strategy and deepening its layout in the new energy field, but also a key initiative where both parties join hands to support the national "Carbon Peaking and Carbon Neutrality" goals and pursue high-quality development. It injects strong momentum into building a new business ecosystem in the Fehorizon Ushers in the 3.0 Era and realizing mutual growth and prosperity with clients.

02 Grand Flight Portfolio Company CF PharmTech Officially Lists on HKEX

On October 8, Grand Flight portfolio company CF PharmTech, Inc. officially listed on the Hong Kong Stock Exchange. As one of the few medical investment institutions in the market with a hospital industry background, Grand Flight has long focused on investment opportunities in core life health industries, and has currently incubated multiple medical listed companies including CF PharmTech (HK.2652), MedBot (HK.2252), MicroPort EP Medtech (SH.688351), and Peijia Medical-B (HK.9996), with the success rate of medical portfolio companies reaching nearly 30%. Meanwhile, several medical portfolio companies of Grand Flight are already in the IPO process, and the IPO success rate of medical enterprises is expected to reach 50% within one year.

03 FEZenith Capital Portfolio Company Xinhuan Technology Completes Series A Financing Led by Medtronic China Fund

On October 27, FEZenith Capital portfolio company Shenzhen Xinhuan Technology Co., Ltd. completed nearly RMB 100 million in Series A financing. This round of financing was led by the Medtronic China Fund, fully demonstrating the recognition from the global medical device leader for Xinhuan Technology's technical strength and sustainable development prospects. As a wholly-owned specialized private equity investment institution of Far East Horizon, FEZenith Capital provides diversified financial services including equity investment, convertible bonds, and merger and acquisition integration in fields such as technological innovation and healthcare. FEZenith Capital participated in Xinhuan Technology's Pre-A+ round financing in December 2023, which is a vivid practice of deeply integrating the financial resources and industrial resources within the Group system to assist portfolio companies in achieving high-quality development.

04 CDHORIZON's CSA Score Reaches New High, Ranking in Global Industry Top 5%

Recently, CDHORIZON achieved a milestone breakthrough in the 2025 S&P Global Corporate Sustainability Assessment (CSA): an annual increase of 10 points, with the total score rising to 58 points, ranking in the global industry top 5%. This not only stems from CDHORIZON's systematic transformations in environmental, social, and governance dimensions but also marks the recognition of its sustainable development practices by international authoritative institutions, laying a solid foundation of trust for deeply integrating into and expanding the global market. In the future, CDHORIZON will use this achievement as a starting point, transforming the sustainable development blueprint into corporate actions, and advancing steadily on the path of high-quality development.

05 CDHORIZON Self-Developed Product Wins China Formwork and Scaffold Association Award

On October 12, CDHORIZON won the "Scientific and Technological Progress Award" from the China Formwork and Scaffold Association for its self-developed "Long U-Head + Truss Beam" product. Since being put into use in 2024, this product has cumulatively achieved an output value of nearly 200 million yuan, saving customers an average of approximately 20 million yuan in costs. Currently, CDHORIZON's self-developed new formwork system is widely used in national major projects and industrial/civil construction fields, ensuring the smooth progress of large-scale construction projects while also widely serving local customers in Southeast Asia, the Middle East, and other regions following CDHORIZON's overseas business strategy. CDHORIZON will adhere to the philosophy of "Collaborating with Global Partners, Building a Better Future," persist in technological leadership, and enable the world to see more possibilities in Chinese construction.

06 HCHORIZON Member Hospital Establishes Medical Consortium with Shanghai East Hospital

On October 11, HCHORIZON member hospital Pizhou Dongda Hospital and Shanghai East Hospital successfully held the unveiling ceremony for the medical consortium and neurology specialty alliance. After the ceremony, senior expert teams from over ten key departments including neurology and cardiovascular medicine of Shanghai East Hospital jointly conducted free clinics and teaching ward rounds, allowing residents of Pizhou to enjoy high-quality medical services from tier-1 city tertiary hospitals locally. This cooperation is another important achievement of HCHORIZON in leveraging high-quality medical resources domestically and internationally to empower member hospital development. Both parties will conduct in-depth collaboration through expert deployments, talent cultivation, and telemedicine, with a focus on enhancing acute stroke treatment capabilities. This is not only a concrete practice in responding to the integrated healthcare development of the Yangtze River Delta but also fulfills HCHORIZON's development mission of "Quality Healthcare Within Reach" through practical actions.